Nature's BioCeuticals Denmark ApSAktiv
Økonomiske nøgletal
Nøgletal
2024/25Balancens sammensætning
Selskabsskat
indkomstår 2023Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk
Regnskabstal2021–2025
| 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 | |
|---|---|---|---|---|---|
| Balance — aktiver | |||||
| Likvide beholdninger | 35.373 | 100 | 100 | 100 | 100 |
| Omsætningsaktiver i alt | — | 57.207 | 103.268 | 92.129 | 119.457 |
| Anlægsaktiver i alt | 190.000 | 14.424.976 | 13.947.732 | 13.578.550 | 12.993.244 |
| Aktiver i alt | 229.984 | 14.482.183 | 14.051.000 | 13.670.679 | 13.112.701 |
| Balance — passiver | |||||
| Kortfristede gældsforpligtelser | 210.000 | 49.094 | 156.748 | 47.647 | 48.191 |
| Langfristede gældsforpligtelser | — | 15.930.249 | 15.046.302 | 15.672.731 | 912.851 |
| Gældsforpligtelser i alt | 210.000 | 15.979.343 | 15.203.050 | 15.720.378 | 961.042 |
| Selskabskapital | 40.000 | 40.000 | 1.600.000 | 1.600.000 | 1.600.000 |
| Overført resultat | -20.016 | -1.537.160 | -2.932.050 | -3.829.699 | 10.371.659 |
| Årets resultat | -20.016 | -1.517.144 | -1.434.890 | -897.649 | -611.024 |
| Egenkapital i alt | 19.984 | -1.497.160 | -1.152.050 | -2.049.699 | 12.151.659 |
| Resultatopgørelse | |||||
| Bruttofortjeneste | -14.627 | -943.913 | -848.625 | -400.403 | -129.477 |
| Resultat af primær drift | — | -1.421.157 | -1.325.869 | -877.647 | -606.721 |
| EBITDA | — | -943.913 | -848.625 | -400.403 | -129.477 |
| Resultat før skat | -24.627 | -1.517.144 | -1.431.690 | -897.649 | -611.024 |
| Årets resultat | -20.016 | -1.517.144 | -1.434.890 | -897.649 | -611.024 |
| Personaleomkostninger | — | — | — | — | — |
| Af- og nedskrivninger | 10.000 | 477.244 | 477.244 | 477.244 | 477.244 |
| Andre nøgletal | |||||
| Ansatte | 1 | — | — | — | 1 |
En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.
Om virksomheden
Årsrapport 2025Description of key activities of the companyLike previous years, the key activities comprise trading and production of medical cannabis and associated activities
Significant changes in the company's activities and financial mattersThere have been no significant changes in activities and financial matters. The gross loss for the year totals DKK -129.477 against DKK -400.403 last year. Profit or loss from ordinary activities after tax totals DKK -611.024 against DKK -897.649 last year. Management considers the net profit or loss for the year satisfactory. Material errors in previous yearsDuring the financial year 2024/25, management has identified significant income related to the financial year 2023/24. This affects the previously issued annual report for 2023/24. As a result, the error has been corrected as a prior period adjustment by restating the comparative figues and the opening equity in the financial statements for 2024/25. For further description of the effect of the correction, reference is made to the company´s accounting policies.
Uddrag af ledelsesberetningen i den seneste årsrapport.